DN Capital, Early Backer of Auto1, Shazam and OLX, Launches New $350m Fund to Shape Post-pandemic World
9.7.2021 07:00:00 EEST | Business Wire | Press release
DN Capital, one of Europe’s most established Venture Capital firms, today announces the launch of its latest $350m (£220m, €300m) fund. In a year which has already seen four of the DN Capital portfolio reach billion dollar-plus valuations, the firm’s Fund V will back the most ambitious early stage entrepreneurs across Europe, the UK and the US, who are creating businesses built on the pandemic-accelerated surge in digital adoption, and developing technologies critical to the global recovery.
Under the leadership of private equity and VC stalwarts Nenad Marovac and Steve Schlenker - who head up a senior team with a combined 100 years-plus of investment experience - DN’s predominantly young and ambitious team has a consistent track record of partnering with some of Europe’s most promising startups, long before they became market leaders.
‘Think Big and Global”
Known for their ‘Think Big and Global’ approach to startup investing, the firm was one of Shazam’s earliest backers in 2004, and helped guide the London-born app through to Apple’s acquisition in 2018. DN Capital led the Series A round in Auto1, which floated on the German Stock Exchange earlier this year at a valuation over $10 billion and over 150x their entry price per share. Just recently in July 2021 the online eyewear retailer MrSpex also saw a strong IPO debut, valuing the company at over $1.0bn. DN Capital’s first billion dollar exit was Endeca which was sold to Oracle for $1.1bn in 2011. In its current portfolio US remittance business Remitly, digital staffing company Jobandtalent and the online education company GoStudent are amongst the latest unicorns and have recently closed billion-dollar financing rounds.
Fund V, which was substantially oversubscribed, will double-down on DN Capital’s strategy of finding and supporting the next generation of global category leaders specifically in its core fields of software, fintech, marketplaces and the consumer internet. Roughly two thirds of the firm’s investments have been made in Europe, through its London and Berlin hubs, with the remainder originating in its Silicon Valley office in Menlo Park.
For the journey
With a proven ability to identify founders with unicorn potential at the earliest stages, a worldwide advisor network, a deep 20-year track record, and a reputation for insightful business model understanding, DN Capital has established itself as a persistent outlier in European and US venture capital. It has proven to give founders the best possible platform for their scale-up journey, while being able to introduce its portfolio teams to top tier growth-stage investors.
“We’ve always preferred to let our founders and their incredible numbers talk for us,” says Nenad Marovac DN Capital’s founder. “When we say we only partner with the best, we mean it. We spend vast amounts of time with entrepreneurs understanding the market, their team, their product and to get to the heart of what they’re trying to achieve, long before we even talk about money. Then we work together with the entrepreneurs as partners to help them where they need it.
“The launch of our fifth fund gives us further scope to uncover new entrepreneurs with the biggest, brightest global ambitions. We pride ourselves on the fact that we work as hard as founders do to help them build their businesses, and this is something that’s going to be even more crucial as we, as a society, look to come back stronger following the pandemic,” he says.
‘Post-COVID fund’
DN Capital co-founder and managing partner Steve Schlenker believes the full impact of the pandemic on society, work, and behaviours is only just being understood, and that—when it happens--the recovery around the world will be powered by innovation and technology. “There are tech founders across the globe right now on critical missions to accelerate this recovery and help address the needs, and solve the biggest problems, of the post-COVID world,” he says. “At DN Capital we are committed to supporting them to achieve these goals.”
Partner Thomas Rubens adds: “We have backed numerous category defining businesses and we know what it takes to scale global companies. We have the youth and ambition in our team, as well as the huge global network, to be right at the cutting-edge of the next important trends. Especially those trends born out of the drastic, era-defining change we are witnessing today.”
“From the very start of our journey, Nenad, who was on our Board throughout, and the wider DN Capital team, supported us not just with strategic advice but helped us launch in the US, hire senior executives—including myself—and also introduced Apple,” says Andrew Fisher, Shazam’s former CEO and executive chairman. “The founder-investor relationship can be make-or-break for early stage entrepreneurs.”
Hakan Koc, co-founder and CEO at Auto1, said: ““ Since DN led the Series A in Auto1 we always enjoyed working with Nenad, Steve and the team. From the outset they saw the potential in us and Auto1 Group and understood how best to support us.”
Felix Ohswald, co-founder and CEO of GoStudent, said: “Expanding into 18 markets in just over two years is never easy but with DN Capital on our side we knew we could do it and in forging the connection with our next investors - DST, Softbank and Tencent - they helped us to take that next big leap.”
--ENDS--
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005769/en/
Contact information
Sayula Kirby
sayula@burlington.cc
+44 7909 985 621
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
